Trebicka Jonel, Praktiknjo Michael, Peiffer Kai-Henrik, Pascher Andreas, Schulz Martin Sebastian, Uschner Frank Erhard
Department of Medicine B, University Hospital Münster (UKM), Münster, Germany; Department of General, Abdominal and Transplantation Surgery, University Hospital Münster (UKM), Münster, Germany.
Dtsch Arztebl Int. 2025 Feb 21;122(4):96-102. doi: 10.3238/arztebl.m2024.0255.
Cirrhosis is the end stage of chronic liver disease. Cirrhosis causes portal hypertension, which, in turn, can lead to acute on chronic liver failure (ACLF), which is defined as acute decompensation combined with failure of the liver, coagulation system, kidneys, lungs, and/or circulatory system, or hepatic encephalopathy.
This review is based on a selective literature search for international publications in the NCBI database using the keywords "liver cirrhosis" and "ACLF." Valid guidelines (up to June 2024) were also included.
Cirrhosis is present in approximately 1% of all hospital admissions in Germany, and complications of cirrhosis cause an estimated 1 million deaths worldwide each year. ACLF, the most severe form of decompensated liver cirrhosis, bears a 28-day mortality of 45% and affects 35% of all patients hospitalized for decompensated cirrhosis. Its precipitating factors are infection, alcohol overuse, bleeding, and drug-induced enceph alopathy (benzodiazepines or opioids). No drugs or other treatments for ACLF have been approved; only its etiology and precipitating factors are amenable to treatment.
Liver transplantation is currently the only curative option for ACLF but is not suitable for all patients because of the narrow therapeutic window and the common presence of contraindications. Prospective data are lacking that would aid in the selection of patients for liver transplantation so that post-transplantation survival rates can be improved.
肝硬化是慢性肝病的终末期。肝硬化会导致门静脉高压,进而可引发慢加急性肝衰竭(ACLF),其定义为急性失代偿合并肝脏、凝血系统、肾脏、肺和/或循环系统功能衰竭,或肝性脑病。
本综述基于在NCBI数据库中使用关键词“肝硬化”和“ACLF”对国际出版物进行的选择性文献检索。还纳入了有效的指南(截至2024年6月)。
在德国,肝硬化约占所有住院患者的1%,肝硬化并发症每年在全球导致约100万人死亡。ACLF是失代偿期肝硬化最严重的形式,28天死亡率为45%,影响35%因失代偿期肝硬化住院的患者。其诱发因素为感染、酗酒、出血和药物性脑病(苯二氮䓬类或阿片类药物)。尚无获批用于治疗ACLF的药物或其他疗法;仅其病因和诱发因素可进行治疗。
肝移植是目前治疗ACLF的唯一治愈性选择,但由于治疗窗口期狭窄且禁忌证普遍存在,并非适用于所有患者。缺乏有助于选择肝移植患者的数据,因此无法提高移植后的生存率。